PMID- 22750067
OWN - NLM
STAT- MEDLINE
DCOM- 20121030
LR  - 20211021
IS  - 1872-9142 (Electronic)
IS  - 0161-5890 (Print)
IS  - 0161-5890 (Linking)
VI  - 52
IP  - 3-4
DP  - 2012 Oct
TI  - Human beta2-glycoprotein I attenuates mouse intestinal ischemia/reperfusion induced 
      injury and inflammation.
PG  - 207-16
LID - 10.1016/j.molimm.2012.05.018 [doi]
AB  - Intestinal ischemia-reperfusion (IR)-induced injury results from a complex 
      cascade of inflammatory components. In the mouse model of intestinal IR, the 
      serum protein, beta2-glycoprotein I (beta2-GPI) binds to the cell surface early in the 
      cascade. The bound beta2-GPI undergoes a conformational change which exposes a 
      neoantigen recognized by naturally occurring antibodies and initiates the 
      complement cascade. We hypothesized that providing additional antigen with 
      exogenous beta2-GPI would alter IR-induced tissue injury. Administration of human 
      but not mouse beta2-GPI attenuated IR-induced tissue damage and prostaglandin E(2) 
      production indicating a physiological difference between beta2-GPI isolated from the 
      two species. To investigate whether structural features were responsible for this 
      physiological difference, we compared the chemical, physical and biochemical 
      properties of the two proteins. Despite possessing 76% amino acid identity and 
      86% sequence homology, we found that mouse beta2-GPI differs from the human protein 
      in size, carbohydrate chain location, heterogeneity and secondary structural 
      content. These data suggest that the structural differences result in mouse Ab 
      recognition of soluble human but not mouse beta2-GPI and attenuated IR-induced 
      injury. We conclude that caution should be exercised in interpreting results 
      obtained by using human beta2-GPI in a mouse model.
CI  - Copyright (c) 2012 Elsevier Ltd. All rights reserved.
FAU - Tomasi, Maurizio
AU  - Tomasi M
AD  - Division of Biology, Kansas State University, Manhattan, KS 66506, United States.
FAU - Hiromasa, Yasuaki
AU  - Hiromasa Y
FAU - Pope, Michael R
AU  - Pope MR
FAU - Gudlur, Sushanth
AU  - Gudlur S
FAU - Tomich, John M
AU  - Tomich JM
FAU - Fleming, Sherry D
AU  - Fleming SD
LA  - eng
GR  - P20 RR017686/RR/NCRR NIH HHS/United States
GR  - RR016475/RR/NCRR NIH HHS/United States
GR  - AI061691/AI/NIAID NIH HHS/United States
GR  - P20 RR016475/RR/NCRR NIH HHS/United States
GR  - R01 AI061691/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20120627
PL  - England
TA  - Mol Immunol
JT  - Molecular immunology
JID - 7905289
RN  - 0 (Homeodomain Proteins)
RN  - 0 (beta 2-Glycoprotein I)
RN  - 128559-51-3 (RAG-1 protein)
RN  - K7Q1JQR04M (Dinoprostone)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Cell Membrane/metabolism
MH  - Dinoprostone/biosynthesis
MH  - Homeodomain Proteins/genetics
MH  - Humans
MH  - Inflammation/*immunology
MH  - Intestines/*immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Protein Structure, Secondary
MH  - Proteomics
MH  - Reperfusion Injury/drug therapy/*immunology
MH  - Sequence Alignment
MH  - beta 2-Glycoprotein I/*chemistry/*immunology/metabolism
PMC - PMC3565431
MID - NIHMS384365
EDAT- 2012/07/04 06:00
MHDA- 2012/10/31 06:00
PMCR- 2013/10/01
CRDT- 2012/07/04 06:00
PHST- 2012/02/20 00:00 [received]
PHST- 2012/05/23 00:00 [revised]
PHST- 2012/05/31 00:00 [accepted]
PHST- 2012/07/04 06:00 [entrez]
PHST- 2012/07/04 06:00 [pubmed]
PHST- 2012/10/31 06:00 [medline]
PHST- 2013/10/01 00:00 [pmc-release]
AID - S0161-5890(12)00319-7 [pii]
AID - 10.1016/j.molimm.2012.05.018 [doi]
PST - ppublish
SO  - Mol Immunol. 2012 Oct;52(3-4):207-16. doi: 10.1016/j.molimm.2012.05.018. Epub 
      2012 Jun 27.